← 返回

释放 NK 细胞用于肺癌的癌症免疫治疗:生物学挑战与临床进展

英文原题:Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.

查看英文原题

Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.

PubMed 2025/08/23(内容时间) J Exp Clin Cancer Res Q1 · IF 14.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞是固有免疫系统的重要组成部分,通过直接细胞溶解活性或对 T 细胞和抗原提呈细胞的免疫调节信号,作为杀伤肿瘤细胞的重要效应细胞。在包括非小细胞肺癌(NSCLC)在内的多种癌症中,NK 细胞与肿瘤控制增强和患者总生存期改善相关。尽管 NK 细胞具有抗肿瘤杀伤的良好潜力,但其功能在肿瘤微环境中常常减弱。导致肿瘤浸润 NK 细胞杀伤功能下降的因素众多,包括来自肿瘤细胞和驻留组织的免疫抑制因子、获得性免疫耐受、NK 细胞耗竭以及肿瘤微环境的缺氧状态。因此,释放 NK 细胞活性具有很大潜力,可创建一类新型免疫疗法,既能对抗当前检查点抑制剂的原发性耐药,也能对抗获得性耐药。在本综述中,我们讨论 NK 细胞杀伤肿瘤的机制细节、NK 细胞免疫抑制,以及在高度复杂的微环境特异性效应对 NK 细胞功能影响方面存在的知识空白。我们还讨论新兴的基于 NK 细胞的治疗策略的前景与局限性。

展开英文摘要原文

Natural killer (NK) cells are a crucial part of the innate immune system and serve as an important effector for killing tumor cells through direct cytolytic activity or immunomodulatory signaling to T cells and antigen presenting cells. NK cells are correlated with increased tumor control and better overall patient survival across various types of cancers including non-small cell lung cancer (NSCLC). Despite their promising potential for anti-tumor killing, NK cell function is often diminished within the tumor microenvironment.

There are many factors that lead to decreased tumor-infiltrating NK cell killing, including immunoinhibitory factors from tumor cells and resident tissues, acquired immune tolerance, NK cell exhaustion, and the hypoxic state of the tumor microenvironment.

Unleashing NK cell activity therefore has high potential to create a new class of immunotherapy that could combat both primary and acquired resistance to current checkpoint inhibitors. In this review we discuss mechanistic details of NK cell tumor killing, NK cell immunosuppression, and gaps in knowledge regarding highly complex microenvironment-specific effects on NK cell function.

We also discuss the promise and limitations of emerging NK-cell based therapeutic strategies.

论文信息

作者
McLaughlin Q、Sojka DK、Kennedy K、Piersma SJ、Sethakorn N
第一作者单位
Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.United States
通讯作者单位
Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. nsethakorn@luc.edu.United States
文献类型
综述
期刊
Journal of experimental & clinical cancer research : CR2025 Aug 23
原文标识
PubMed 40849493 · DOI 10.1186/s13046-025-03503-7